Acelrx Pharmaceuticals Inc organizacji RSI
Jaka jest wartość RSI organizacji Acelrx Pharmaceuticals Inc?
Wartość RSI organizacji Acelrx Pharmaceuticals Inc to 45.25
Jaka jest definicja RSI?
Wskaźnik względnej siły (Relative strength index - RSI 14) jest wskaźnikiem technicznym, który plasuje się pomiędzy wskaźnikami momentu i mierzy prędkość i zmianę ceny. Jego wartość wynosi od 0 do 100 i służy do scharakteryzowania stanu sprzed zakupu i przedpłaty.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI firm w Health Care sektor na NASDAQ w porównaniu do Acelrx Pharmaceuticals Inc
Czym się zajmuję organizacja Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Firmy z rsi podobne do Acelrx Pharmaceuticals Inc
- Wartość RSI organizacji Baytex to 45.23
- Wartość RSI organizacji Minco Silver to 45.24
- Wartość RSI organizacji Alerus Corp to 45.24
- Wartość RSI organizacji TransAlta Renewables to 45.24
- Wartość RSI organizacji Cryo-Cell International to 45.24
- Wartość RSI organizacji NP3 Fastigheter AB (publ) to 45.24
- Wartość RSI organizacji Acelrx Pharmaceuticals Inc to 45.25
- Wartość RSI organizacji Clear Blue Technologies International to 45.26
- Wartość RSI organizacji Geomega Resources to 45.26
- Wartość RSI organizacji Portman Ridge Finance Corp to 45.26
- Wartość RSI organizacji Boralex to 45.27
- Wartość RSI organizacji TUI AG to 45.27
- Wartość RSI organizacji Insmed Inc to 45.27